ITGA2B and Glanzmann thrombasthenia 1: In the case of these three GT patients, after a complete clinical and laboratory workup, including platelet aggregation tests, FCA confirmed the absence of GPIIb/IIIa at the platelet surface in all three GT patients and the impaired binding of PAC-1 following activation with increasing doses of ADP, THR, and CVX.